<DOC>
	<DOCNO>NCT00545246</DOCNO>
	<brief_summary>The primary objective study determine dose aflibercept studied combination docetaxel Japanese cancer patient . The secondary objective study assess safety profile aflibercept , determine pharmacokinetics aflibercept , make preliminary assessment antitumor effect .</brief_summary>
	<brief_title>A Phase I Study Intravenous Aflibercept Combination With Docetaxel Japanese Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm cancer patient without standard care ECOG performance status 0 1 Adequate organ bone marrow function Need major surgery radiation therapy study History hypersensitivity docetaxel polysorbate 80 Treatment chemotherapy , hormonal therapy , radiotherapy within 28 day Uncontrolled hypertension History brain metastasis Ascites require drainage Pregnancy breastfeeding Patients previously treat aflibercept . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>VEGF Trap</keyword>
</DOC>